Glenmark Pharmaceuticals Ltd. continues to push ahead with regional deals for some of its novel assets, this time licensing out its investigational rhinitis therapy, Ryaltris, to Yuhan Corp. in South Korea. (Also see "Glenmark Sets Sights On Regional Out-Licensing, Lot Riding On US Rhinitis NDA" - Scrip, 31 May, 2018.)
The Indian firm, which is keen to move up the innovation value chain from a largely pure-generics play, said that...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
